Hypoxia and Medicine

Myocardial Ischemia News

Molecular Insights Zemiva Demonstrates Ability to Significantly Improve Early Diagnosis of the Chest Pain Patient in ...Tuesday, December 23, 2008 @ 6:00AM CAMBRIDGE, Mass.----Molecular Insight Pharmaceuticals, Inc. announced today that results from a recently completed Phase 2 clinical study suggest that Zemiva, when combined with the standard of care for the diagnostic evaluation of the chest pain patient, significantly improved the detection of cardiac ischemia when compared to the standard of care alone.

Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small VesselsWednesday, December 17, 2008 @ 12:52PM Abbott today announced the start of SPIRIT Small Vessel, a clinical trial evaluating a 2.25 mm size of the XIENCE V Everolimus Eluting Coronary Stent System. The 2.25 mm stent system would offer physicians an option for treating coronary artery disease in narrower vessels that is based on the proven efficacy, safety and deliverability of XIENCE V.

Capstone Therapeutics Announces Third Quarter 2008 Financial ResultsThursday, November 6, 2008 @ 6:00AM TEMPE, Ariz., Nov. 6, 2008 -- Capstone Therapeutics , trade name of OrthoLogic Corp. , today announced financial results for the third quarter 2008.

Canadian Study Finds Heart Rate-Lowering Drug Improves Exercise Capacity In Patients With Stable AnginaFriday, October 31, 2008 @ 6:15AMResults from a late-breaking clinical trial, presented at the 2008 Canadian Cardiology Congress (CCC) in Toronto, show for the first time that combining the pure heart rate reduction medication ivabradine to current treatments of patients with stable angina improves their exercise capacity.

GlaxoSmithKline believes there is no liver safety issue with Avandia (rosiglitazone maleate)Friday, October 31, 2008 @ 4:25AMGlaxoSmithKline today issued the following response to a petition filed by Public Citizen to the U.S. Food and Drug Administration (FDA) on Avandia (rosiglitazone maleate), a highly effective therapy for treating type 2 diabetes when used in the appropriate patient population.